Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0105 | 0.2952 | 0.2952 |
Schistosoma mansoni | hypothetical protein | 0.0284 | 0.9276 | 0.9276 |
Echinococcus multilocularis | Bcl 2 ous antagonist:killer | 0.0284 | 0.9276 | 1 |
Echinococcus multilocularis | gcn5proteinral control of amino acid synthesis | 0.0162 | 0.4943 | 0.5329 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0105 | 0.2952 | 0.2952 |
Plasmodium falciparum | histone acetyltransferase GCN5 | 0.0044 | 0.0775 | 1 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.0157 | 0.4783 | 0.5156 |
Schistosoma mansoni | glutaminase | 0.0305 | 1 | 1 |
Schistosoma mansoni | bcl-2 homologous antagonist/killer (bak) | 0.0284 | 0.9276 | 0.9276 |
Trichomonas vaginalis | bromodomain-containing protein, putative | 0.0048 | 0.0914 | 0.0914 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.0048 | 0.0914 | 0.0986 |
Schistosoma mansoni | hypothetical protein | 0.0284 | 0.9276 | 0.9276 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0105 | 0.2952 | 0.3182 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0022 | 0 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0105 | 0.2952 | 0.2952 |
Loa Loa (eye worm) | apoptosis regulator protein | 0.0284 | 0.9276 | 0.9276 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0022 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0022 | 0 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0022 | 0 | 0.5 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-B | 0.0048 | 0.0914 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0022 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0284 | 0.9276 | 0.9276 |
Schistosoma mansoni | hypothetical protein | 0.0284 | 0.9276 | 0.9276 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0022 | 0 | 0.5 |
Trichomonas vaginalis | glutaminase, putative | 0.0305 | 1 | 1 |
Giardia lamblia | Histone acetyltransferase GCN5 | 0.0044 | 0.0775 | 1 |
Trichomonas vaginalis | cat eye syndrome critical region protein 2, cscr2, putative | 0.0048 | 0.0914 | 0.0914 |
Mycobacterium ulcerans | glutaminase | 0.0305 | 1 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0105 | 0.2952 | 0.2952 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0105 | 0.2952 | 0.3182 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0105 | 0.2952 | 0.3182 |
Loa Loa (eye worm) | acetyltransferase | 0.0162 | 0.4943 | 0.4943 |
Echinococcus granulosus | Bcl 2 ous antagonist:killer | 0.0284 | 0.9276 | 1 |
Loa Loa (eye worm) | glutaminase | 0.0305 | 1 | 1 |
Echinococcus granulosus | EGFP:Bcl2 fusion protein | 0.0284 | 0.9276 | 1 |
Loa Loa (eye worm) | glutaminase 2 | 0.0305 | 1 | 1 |
Echinococcus multilocularis | EGFP:Bcl2 fusion protein | 0.0284 | 0.9276 | 1 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-A | 0.0048 | 0.0914 | 1 |
Schistosoma mansoni | apoptosis regulator bax | 0.0284 | 0.9276 | 0.9276 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0105 | 0.2952 | 0.2952 |
Entamoeba histolytica | acetyltransferase, GNAT family | 0.0044 | 0.0775 | 1 |
Brugia malayi | acetyltransferase, GNAT family protein | 0.0162 | 0.4943 | 0.4943 |
Plasmodium vivax | histone acetyltransferase GCN5, putative | 0.0048 | 0.0914 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0105 | 0.2952 | 0.3182 |
Brugia malayi | Apoptosis regulator proteins, Bcl-2 family protein | 0.0284 | 0.9276 | 0.9276 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0022 | 0 | 0.5 |
Schistosoma mansoni | gcn5proteinral control of amino-acid synthesis 5-like 2 gcnl2 | 0.0162 | 0.4943 | 0.4943 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0023 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | = 89.1251 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.